搜尋
Nuvation Bio Inc
NUVB添加自選
6.260USD
-0.070-1.11%
交易中 （美東）報價延遲15分鐘
2.17B總市值
虧損本益比TTM
關於 Nuvation Bio Inc 公司
Nuvation Bio Inc. is a global biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The Company's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Nuvation Bio Inc簡介
公司代碼NUVB
公司名稱Nuvation Bio Inc
上市日期Jul 01, 2020
CEOHung (David T)
員工數量220
證券類型Ordinary Share
年結日Jul 01
公司地址1500 Broadway
城市NEW YORK
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編10036
電話13322086102
網址https://www.nuvationbio.com/
公司代碼NUVB
上市日期Jul 01, 2020
CEOHung (David T)
Nuvation Bio Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
59.28M
-1.69%
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
200.00K
+50.00%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+64.10%
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
61.37K
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
12.67K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Dr. Gary Hattersley, Ph.D.
Dr. Gary Hattersley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
59.28M
-1.69%
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
200.00K
+50.00%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+64.10%
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
61.37K
--
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
常見問題
Nuvation Bio Inc的前五大股東是誰？
Nuvation Bio Inc的前五大股東如下：Dr. David T. Hung, M.D.
有多少機構持有Nuvation Bio Inc(NUVB)的股份？
截至2026Q1，共有421家機構持有Nuvation Bio Inc的股份，合計持有的股份價值約為228.36M，占公司總股份的65.58% 。與2025Q4相比，機構持股有所增加，增幅為-32847901.00。